MK-5684 vs Abiraterone or Enzalutamide in patients with mCRPC who have progressed on 1 prior NHA

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Wytheville, Salem

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

For More Information:

https://clinicaltrials.gov/study/NCT06136650?term=MK-5684&rank=4